These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 37641687)

  • 21. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review.
    Kumar V; Singh P; Gupta SK; Ali V; Verma M
    Mol Cell Biochem; 2022 Apr; 477(4):1261-1279. PubMed ID: 35129779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asciminib: First Approval.
    Deeks ED
    Drugs; 2022 Feb; 82(2):219-226. PubMed ID: 35041175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of chronic myeloid leukemia in 2023 - common ground and common sense.
    Senapati J; Sasaki K; Issa GC; Lipton JH; Radich JP; Jabbour E; Kantarjian HM
    Blood Cancer J; 2023 Apr; 13(1):58. PubMed ID: 37088793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review.
    Atallah E; Saini L; Maegawa R; Rajput T; Corbin R; Viana R
    Ther Adv Hematol; 2023; 14():20406207221150305. PubMed ID: 38105770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells.
    Okabe S; Moriyama M; Gotoh A
    World J Oncol; 2024 Apr; 15(2):319-324. PubMed ID: 38545482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.
    Combes FP; Li YF; Hoch M; Lorenzo S; Ho YY; Sy SKB
    Clin Pharmacol Ther; 2022 Nov; 112(5):1040-1050. PubMed ID: 35776072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
    Khadadah FM; Cerquozzi S; Olney HJ; Fraga C; Dudebout J; Xenocostas A; Finn N; Ethier V; Savoie ML; Busque L; Jamani K; Kuruvilla P; Faught C; Leber B; Kaedbey R; Assouline SE; Kim D
    Leuk Res; 2023 Oct; 133():107374. PubMed ID: 37657146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of TKI-resistant chronic phase CML.
    Hughes TP; Shanmuganathan N
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):129-137. PubMed ID: 36485117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    Hochhaus A; Wang J; Kim DW; Kim DDH; Mayer J; Goh YT; le Coutre P; Takahashi N; Kim I; Etienne G; Andorsky D; Issa GC; Larson RA; Bombaci F; Kapoor S; McCulloch T; Malek K; Yau L; Ifrah S; Hoch M; Cortes JE; Hughes TP;
    N Engl J Med; 2024 Sep; 391(10):885-898. PubMed ID: 38820078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation.
    Uhm J
    Blood Res; 2023 Apr; 58(S1):109-113. PubMed ID: 37105565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
    Haddad FG; Issa GC; Jabbour E; Yilmaz M
    Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.
    Pamuk GE; Chow ECY; Ionan AC; Chen H; Lee SL; Hsu V; Grimstein M; Zheng N; Sun J; Charlab R; Gehrke BJ; Vallejo J; Ehrlich LA; de Claro RA; Theoret MR
    Clin Cancer Res; 2024 Aug; ():. PubMed ID: 39088257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asciminib: an investigational agent for the treatment of chronic myeloid leukemia.
    Breccia M; Colafigli G; Scalzulli E; Martelli M
    Expert Opin Investig Drugs; 2021 Aug; 30(8):803-811. PubMed ID: 34130563
    [No Abstract]   [Full Text] [Related]  

  • 36. Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance.
    Yoshimaru R; Minami Y
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
    Luna A; Pérez-Lamas L; Boque C; Giraldo P; Xicoy B; Ruiz Nuño C; Vega MM; Alvarez-Larrán A; Salamanca A; García-Noblejas A; Vall-Llovera F; Villalon L; De Las Heras N; Ramila E; Pérez-Encinas M; Cuevas B; Perez-Lopez R; Sanchez-Guijo F; Jiménez-Velasco A; Lakhwani S; Casado LF; Rosell A; Escola A; Fernández MJ; Garcia-Hernandez C; Cervero C; Mora E; Sagüés M; Suarez-Varela S; Vélez P; Carrascosa Mastell P; Bitaube RF; Serrano L; Cortes M; Vera Goñi JA; Steegmann JL; de Soria VGG; Alonso-Dominguez JM; Araujo MC; Coll AP; Hernandez-Boluda JC; García-Gutiérrez V
    Ann Hematol; 2022 Oct; 101(10):2263-2270. PubMed ID: 35997804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
    García-Gutiérrez V; Breccia M; Jabbour E; Mauro M; Cortes JE
    J Hematol Oncol; 2022 Jul; 15(1):90. PubMed ID: 35818053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia.
    Kantarjian HM; Jabbour E; Deininger M; Abruzzese E; Apperley J; Cortes J; Chuah C; DeAngelo DJ; DiPersio J; Hochhaus A; Lipton J; Nicolini FE; Pinilla-Ibarz J; Rea D; Rosti G; Rousselot P; Shah NP; Talpaz M; Srivastava S; Ren X; Mauro M
    Am J Hematol; 2022 Nov; 97(11):1419-1426. PubMed ID: 36054756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia.
    Westerweel PE; Te Boekhorst PAW; Levin MD; Cornelissen JJ
    Front Oncol; 2019; 9():665. PubMed ID: 31448223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.